Corcept Therapeutics Incorporated (CORT) : Traders are bullish on Corcept Therapeutics Incorporated (CORT) as it has outperformed the S&P 500 by a wide margin of 6.31% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.55%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.11% in the last 1 week, and is up 4.16% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3.74% and the 50-Day Moving Average is 0.69%.The 200 Day SMA reached 17.17% Corcept Therapeutics Incorporated is up 9.09% in the last 3-month period. Year-to-Date the stock performance stands at 15.66%.
Corcept Therapeutics Incorporated (CORT) : Average target price received by Corcept Therapeutics Incorporated (CORT) is $9.25 with an expected standard deviation of $3.4. The most aggressive target on the stock is $12, whereas the most downbeat target is $5. 4 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. Corcept Therapeutics Incorporated (NASDAQ:CORT): The stock opened at $5.78 and touched an intraday high of $5.8 on Friday. During the day, the stock corrected to an intraday low of $5.68, however, the bulls stepped in and pushed the price higher to close in the green at $5.76 with a gain of 0.17% for the day. The total traded volume for the day was 1,075,474. The stock had closed at $5.76 in the previous trading session.
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Companys focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders. It is developing mifepristone, a potent glucocorticoid receptor (GR) antagonist that modulates the activity of cortisol for the treatment of a number of severe metabolic, psychiatric and oncologic disorders. The Company also discovered three series of selective GR antagonists. As of December 31, 2014, it had commenced enrollment in a Phase I clinical study with CORT125134. The Company has completed Phase I trials of CORT108297 for the treatment of central nervous system disorders. The Companys product Korlym contains 300 milligram mifepristone for the treatment of hyperglycemia.